Kyverna Therapeutics, Immunome, Almonty Industries, and Other Major Stocks Rise on Monday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Should l Buy OLMA?
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks declined, with the Nasdaq Composite dropping over 100 points on Monday.
Kyverna Therapeutics Surge: Kyverna Therapeutics Inc. shares rose 31% to $11.49 following the announcement of positive topline data from its Phase 2 trial of mivocabtagene autoleucel for stiff person syndrome.
Other Notable Stock Gains: Beneficient, Immunome Inc., and Falcon’s Beyond Global recorded significant gains, with increases of 29.3%, 25.5%, and 14% respectively.
Additional Stock Movements: Several other companies, including Almonty Industries and NovaBay Pharmaceuticals, also saw notable increases in their stock prices, contributing to a generally positive day for select stocks despite the overall market decline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OLMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OLMA
Wall Street analysts forecast OLMA stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.960
Low
20.00
Averages
42.00
High
60.00
Current: 14.960
Low
20.00
Averages
42.00
High
60.00
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cormorant Asset Management Initiates Position in Olema Pharmaceuticals
- New Investment Move: Cormorant Asset Management initiated a position in Olema Pharmaceuticals in Q4 2026, acquiring 2.75 million shares worth $68.75 million, reflecting strong confidence in the company's future prospects.
- Significant Holding Proportion: This investment represents 3.18% of Cormorant's 13F reportable AUM as of December 31, 2025, highlighting its importance within the fund's portfolio.
- Outstanding Market Performance: Olema shares are currently priced at $16.60, having surged 276% over the past year, significantly outperforming the S&P 500's approximately 19% gain, indicating strong market recognition of its potential.
- Clinical Progress Outlook: Olema's lead product OP-1250 is in Phase 1/2 clinical trials for ER-positive, HER2-negative breast cancer, and if successful, could lead to significant commercialization opportunities, with potential market entry as early as 2027.
See More
Olema Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Performance: Olema Pharmaceuticals reported a Q4 GAAP EPS of -$0.50, beating market expectations of -$0.51, indicating improvements in cost management despite ongoing losses.
- Cash Reserves: As of December 31, 2025, Olema's cash, cash equivalents, and marketable securities totaled $505.4 million, providing substantial funding for future R&D and operations, thereby enhancing financial stability.
- Executive Departure: The departure of Olema's Chief Operating Officer and Chief Financial Officer may have short-term implications for strategic execution and financial management, necessitating close monitoring of subsequent executive appointments and their impact on operations.
- Market Engagement: Olema actively showcased its latest developments at several key conferences, including Citi's 2026 Virtual Oncology Leadership Summit and the J.P. Morgan Healthcare Conference, indicating the company's commitment to attracting investor attention and advancing its oncology drug development pipeline.
See More
Olema Pharmaceuticals Stock Plummets Amid Clinical Trial Developments
- Disappointing Clinical Results: Roche's phase 3 study of giredestrant combined with palbociclib failed to show a statistically significant improvement in progression-free survival compared to letrozole, leading to decreased market confidence in Olema and pressuring its stock price.
- Optimistic Progress for Palazestrant: Olema's lead candidate, Palazestrant, is a novel oral estrogen receptor antagonist undergoing various breast cancer trials, and despite challenges, the market remains optimistic about its potential.
- Bearish Technical Indicators: The stock is currently trading 26.2% below its 20-day SMA and 19% below its 100-day SMA, indicating a bearish trend in the short term, prompting caution among investors.
- Price Movement Analysis: Olema shares fell 2.54% to $15.36 on Wednesday, and while the stock has surged 294.05% over the past year, it is now closer to its 52-week lows, reflecting market uncertainty.
See More
Olema Pharmaceuticals and Capital One See High Options Trading Volume
- Olema Options Volume: Olema Pharmaceuticals Inc saw options trading volume of 6,864 contracts, equating to approximately 686,400 shares, which represents about 55.1% of its average daily trading volume of 1.2 million shares over the past month, indicating heightened market interest in its future performance.
- High Put Option Activity: Notably, the $14 strike put option expiring on April 17, 2026, has seen 2,044 contracts traded today, representing around 204,400 underlying shares, suggesting increased investor expectations for a price decline.
- Capital One Options Trading: Capital One Financial Corp experienced options trading volume of 27,954 contracts, translating to approximately 2.8 million shares, or about 51.7% of its average daily trading volume of 5.4 million shares over the past month, reflecting market attention on its stock volatility.
- Active Put Option Trading: Particularly, the $220 strike put option expiring on March 20, 2026, has recorded 4,806 contracts traded today, representing about 480,600 underlying shares, indicating a cautious outlook from investors regarding Capital One's future performance.
See More
DJS Law Group Investigates Olema Pharmaceuticals Investor Claims
- Investigation Background: DJS Law Group has announced an investigation into claims on behalf of investors of Olema Pharmaceuticals (NASDAQ:OLMA), focusing on potential violations of securities laws, including misleading statements or failure to disclose critical information.
- Market Reaction: Following a report from Investor's Business Daily on March 9, 2026, regarding the failure of a Roche trial for an oral breast cancer medication, Olema's shares fell by over 19.6% in morning trading, indicating significant investor concern.
- Analyst Insights: Analyst Matthew Biegler highlighted that the Roche trial results negatively impact the thesis that oral SERDs can succeed in front-line breast cancer treatment, raising further doubts about Olema's competitive position in the market.
- Legal Service Commitment: DJS Law Group is dedicated to enhancing investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation, aiming to provide high-value legal services to its clients.
See More
Oil Price Surge Drives Significant Stock Movements
- Oil Price Impact: Oil prices surged past $110 per barrel due to the ongoing Iran conflict, leading Chevron to hit an all-time high, while Talos Energy rose by 5%, and ConocoPhillips and Northern Oil gained 2% and 3% respectively, indicating strong performance among oil companies in a high-price environment.
- Hims & Hers Health Surge: The company's stock soared 39% after striking a deal with Novo Nordisk to sell its weight-loss drug, resolving a lawsuit over a copycat version, which is expected to significantly enhance its market share and brand reputation.
- Live Nation Settlement Near: Live Nation's shares rose 6% as it nears a settlement with the Department of Justice regarding monopoly allegations in the live concert industry, which, if successful, will stabilize and expand its future business operations.
- United Therapeutics Buyback Plan: The pharmaceutical company's shares increased by over 8% after its board authorized a $2 billion stock repurchase plan, with $1.5 billion allocated for accelerated buybacks, which is expected to boost investor confidence and enhance shareholder value.
See More
Cormorant Asset Management Initiates Position in Olema Pharmaceuticals
- New Investment Move: Cormorant Asset Management initiated a position in Olema Pharmaceuticals in Q4 2026, acquiring 2.75 million shares worth $68.75 million, reflecting strong confidence in the company's future prospects.
- Significant Holding Proportion: This investment represents 3.18% of Cormorant's 13F reportable AUM as of December 31, 2025, highlighting its importance within the fund's portfolio.
- Outstanding Market Performance: Olema shares are currently priced at $16.60, having surged 276% over the past year, significantly outperforming the S&P 500's approximately 19% gain, indicating strong market recognition of its potential.
- Clinical Progress Outlook: Olema's lead product OP-1250 is in Phase 1/2 clinical trials for ER-positive, HER2-negative breast cancer, and if successful, could lead to significant commercialization opportunities, with potential market entry as early as 2027.
See More
Olema Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Performance: Olema Pharmaceuticals reported a Q4 GAAP EPS of -$0.50, beating market expectations of -$0.51, indicating improvements in cost management despite ongoing losses.
- Cash Reserves: As of December 31, 2025, Olema's cash, cash equivalents, and marketable securities totaled $505.4 million, providing substantial funding for future R&D and operations, thereby enhancing financial stability.
- Executive Departure: The departure of Olema's Chief Operating Officer and Chief Financial Officer may have short-term implications for strategic execution and financial management, necessitating close monitoring of subsequent executive appointments and their impact on operations.
- Market Engagement: Olema actively showcased its latest developments at several key conferences, including Citi's 2026 Virtual Oncology Leadership Summit and the J.P. Morgan Healthcare Conference, indicating the company's commitment to attracting investor attention and advancing its oncology drug development pipeline.
See More
Olema Pharmaceuticals Stock Plummets Amid Clinical Trial Developments
- Disappointing Clinical Results: Roche's phase 3 study of giredestrant combined with palbociclib failed to show a statistically significant improvement in progression-free survival compared to letrozole, leading to decreased market confidence in Olema and pressuring its stock price.
- Optimistic Progress for Palazestrant: Olema's lead candidate, Palazestrant, is a novel oral estrogen receptor antagonist undergoing various breast cancer trials, and despite challenges, the market remains optimistic about its potential.
- Bearish Technical Indicators: The stock is currently trading 26.2% below its 20-day SMA and 19% below its 100-day SMA, indicating a bearish trend in the short term, prompting caution among investors.
- Price Movement Analysis: Olema shares fell 2.54% to $15.36 on Wednesday, and while the stock has surged 294.05% over the past year, it is now closer to its 52-week lows, reflecting market uncertainty.
See More
Olema Pharmaceuticals and Capital One See High Options Trading Volume
- Olema Options Volume: Olema Pharmaceuticals Inc saw options trading volume of 6,864 contracts, equating to approximately 686,400 shares, which represents about 55.1% of its average daily trading volume of 1.2 million shares over the past month, indicating heightened market interest in its future performance.
- High Put Option Activity: Notably, the $14 strike put option expiring on April 17, 2026, has seen 2,044 contracts traded today, representing around 204,400 underlying shares, suggesting increased investor expectations for a price decline.
- Capital One Options Trading: Capital One Financial Corp experienced options trading volume of 27,954 contracts, translating to approximately 2.8 million shares, or about 51.7% of its average daily trading volume of 5.4 million shares over the past month, reflecting market attention on its stock volatility.
- Active Put Option Trading: Particularly, the $220 strike put option expiring on March 20, 2026, has recorded 4,806 contracts traded today, representing about 480,600 underlying shares, indicating a cautious outlook from investors regarding Capital One's future performance.
See More
DJS Law Group Investigates Olema Pharmaceuticals Investor Claims
- Investigation Background: DJS Law Group has announced an investigation into claims on behalf of investors of Olema Pharmaceuticals (NASDAQ:OLMA), focusing on potential violations of securities laws, including misleading statements or failure to disclose critical information.
- Market Reaction: Following a report from Investor's Business Daily on March 9, 2026, regarding the failure of a Roche trial for an oral breast cancer medication, Olema's shares fell by over 19.6% in morning trading, indicating significant investor concern.
- Analyst Insights: Analyst Matthew Biegler highlighted that the Roche trial results negatively impact the thesis that oral SERDs can succeed in front-line breast cancer treatment, raising further doubts about Olema's competitive position in the market.
- Legal Service Commitment: DJS Law Group is dedicated to enhancing investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation, aiming to provide high-value legal services to its clients.
See More
Oil Price Surge Drives Significant Stock Movements
- Oil Price Impact: Oil prices surged past $110 per barrel due to the ongoing Iran conflict, leading Chevron to hit an all-time high, while Talos Energy rose by 5%, and ConocoPhillips and Northern Oil gained 2% and 3% respectively, indicating strong performance among oil companies in a high-price environment.
- Hims & Hers Health Surge: The company's stock soared 39% after striking a deal with Novo Nordisk to sell its weight-loss drug, resolving a lawsuit over a copycat version, which is expected to significantly enhance its market share and brand reputation.
- Live Nation Settlement Near: Live Nation's shares rose 6% as it nears a settlement with the Department of Justice regarding monopoly allegations in the live concert industry, which, if successful, will stabilize and expand its future business operations.
- United Therapeutics Buyback Plan: The pharmaceutical company's shares increased by over 8% after its board authorized a $2 billion stock repurchase plan, with $1.5 billion allocated for accelerated buybacks, which is expected to boost investor confidence and enhance shareholder value.
See More
